Tirbanibulin

皮科求索   J Am Acad Dermatol、Br J Dermatol、 JAMA Dermatol、J Eur Acad Dermatol Venereol 皮肤科权威杂志 最新文章抢先看 ！！省去点官网的烦恼！！   顶刊速览   *仅供医学专业人士阅读 本期介绍 本期推送2026年4月《欧洲皮肤病与性病学杂志》（JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY & VENREOLOGY , JEADV）最新发表的文献。 https://onlinelibrary.wiley.com/journal/14683083 文献速览| 目录 注：标题粗体者可至下文浏览摘要/总结 _ 1.针对白皙肤色人群的紫外线辐射防护建议 DOI:10.1111/jdv.70148 2.司库奇尤单抗治疗儿童重度斑块状银屑病的长期安全性与疗效：236周III期试验结果 DOI:10.1111/jdv.70155 3.超声在化脓性汗腺炎中应用的国际共识声明 DOI:10.1111/jdv.20600 4.苯甲酸苄酯和伊维菌素治疗疥疮的疗效优于氯菊酯：一项多中心研究 DOI:10.1111/jdv.70015 5.慢性手部湿疹：EADV接触性皮炎工作组的常见问题与实用建议 DOI:10.1111/jdv.70068 6.生物制剂治疗儿童斑块状银屑病的系统综述与网络Meta分析 DOI:10.1111/jdv.70084 7.口服磷酸二酯酶4抑制剂ME3183治疗斑块状银屑病患者的有效性与安全性 DOI10.1111/jdv.20863 _ 8.生物制剂治疗化脓性汗腺炎的有效性与安全性：基于III期试验的网络Meta分析 DOI:10.1111/jdv.20617 _ 9.生物制剂治疗中重度化脓性汗腺炎的短期疗效：系统综述与网络Meta分析 DOI:10.1111/jdv.70265 _ 10.生物制剂治疗化脓性汗腺炎的升级标准制定探讨 DOI:10.1111/jdv.70118 _ 11.白癜风的临床异质性：基于临床标志物的患者聚类识别 DOI:10.1111/jdv.20785 _ 12.国际专家与色素性疾病学会关于黄褐斑管理的德尔菲共识 DOI:10.1111/jdv.70066 _ 13.Dazukibart治疗重症TIF1γ阳性幼年型皮肌炎 DOI:10.1111/jdv.70059 _ 14.在老年局部进展期基底细胞癌患者中的安全性：一项多中心研究 DOI:10.1111/jdv.20835 _ 15.妊娠期快速进展黑色素瘤转移的控制 DOI:10.1111/jdv.20837 _ 16.1%替巴尼布林软膏治疗浅表性基底细胞癌：一项回顾性研究 DOI:10.1111/jdv.20844 _ 17.头皮皮肤鳞状细胞癌切缘过近或切缘阳性的危险因素 DOI:10.1111/jdv.20872 _ 18.2022年全球皮肤癌流行病学分析及其与皮肤科医生密度的相关性 DOI:10.1111/jdv.20883 _ 19.Stevens-Johnson综合征与中毒性表皮坏死松解症中创伤后应激障碍的患病率及预测因素 DOI:10.1111/jdv.20891 _ 20.免疫检查点抑制剂在自身免疫性大疱性皮肤病患者中的应用：基于系统综述的见解 DOI:10.1111/jdv.70007 _ 21.非烟草尼古丁依赖与Mohs术后并发症：一项回顾性分析 DOI:10.1111/jdv.70013 _ 22.化脓性汗腺炎患者发生皮肤鳞状细胞癌的风险增加：一项配对队列研究 DOI:10.1111/jdv.70055 _ 23.IL-23抑制剂同类药物切换治疗银屑病的系统综述 DOI:10.1111/jdv.70197 精选文献| 摘要： 1.针对白皙肤色人群的紫外线辐射防护建议 研究目的：针对白皙皮肤人群，制定一份基于证据、国际通用的紫外线防护公众教育宣传单，以提升防护信息的传播效果与行为转化率。 研究方法：遵循健康促进材料开发指南，以最新科学共识为依据，借助人工智能生成初稿，并经皮肤肿瘤学、流行病学、公共卫生专家及患者代表等多方多轮反馈修订。 研究结果与结论：宣传单确立三条核心建议：避免日晒与晒黑；以衣物、遮阳帽、阴凉为主；防晒霜为辅。内容涵盖儿童防护、禁用日光浴床、皮肤自我监测及常见问题解答。实现有效防护需转变公众态度并采用针对性宣传策略。宣传单将免费分发，未来需政策层面推动公共遮阳设施建设与晒黑场所监管。 2.司库奇尤单抗治疗儿童重度斑块状银屑病的长期安全性与疗效：236周III期试验结果 研究目的：评估司库奇尤单抗在6岁至18岁以下重度慢性斑块状银屑病患者中治疗236周的长期安全性及有效性。 研究方法：基于一项 III 期随机对照试验的扩展期数据，患者接受司库奇尤单抗低剂量或高剂量治疗，评估至第 236 周的银屑病面积和严重程度指数（PASI）75/90/100应答、改良版研究者整体评估（IGA mod 2011）0/1应答、儿童皮肤病生活质量指数（CDLQI）及不良事件。 研究结果与结论：第236周时，低剂量组与高剂量组的IGA 0/1应答率分别为69.4%和79.5%；PASI 75应答率为97.2%和97.4%；PASI 100应答率为50.0%和69.2%；CDLQI 0/1应答率为64.3%和67.7%。最常见不良事件为鼻咽炎、头痛和扁桃体炎，未出现新的安全性信号。司库奇尤单抗在儿童重度斑块状银屑病长达236周的治疗中显示出持续良好的疗效和可接受的安全性。 3.超声在化脓性汗腺炎中应用的国际共识声明 研究目的：针对化脓性汗腺炎（HS）中超声的应用，制定并验证一项国际共识声明，以规范其诊断、分期、监测及治疗指导等方面的使用。 研究方法：采用三轮德尔菲法，邀请来自四大洲 14 个国家、日常工作中使用超声评估 HS 的 24 位专家参与。围绕超声检查的适应证、技术参数、培训要求、诊断标准、分期系统、监测策略、超声引导下操作及手术计划、临床试验应用等主题进行问卷评分。共识定义为“非常同意”与“同意”合计比例 ≥70%。 研究结果与结论：全部陈述中有96.4%达成共识。超声被明确推荐用于化脓性汗腺炎的诊断、早期病变检测、严重程度与活动度评分、疗效监测、术前规划及临床研究。假性囊肿、液体聚集和隧道等超声下关键病变的定义及分型获得高度认可。该共识证实超声在化脓性汗腺炎全程管理中的重要作用，建议将其标准化纳入临床实践及未来药物试验与研究方案。 4.苯甲酸苄酯和伊维菌素治疗疥疮的疗效优于氯菊酯：一项多中心研究 研究目的：比较苯甲酸苄酯、伊维菌素及氯菊酯单药或联合治疗疥疮的疗效，为耐药背景下优化治疗方案提供依据。 研究方法：开展回顾性多中心研究，纳入2020年1月至2024年6月期间确诊并治疗的727例疥疮患者。治疗结束后2周评估总体应答率和一线治疗应答率，并校正性别、年龄及国籍等因素进行分析。 研究结果及结论：氯菊酯单药疗效最低，总体应答率约65%；苯甲酸苄酯25%联合口服伊维菌素疗效最高，达97%。其他方案如苯甲酸苄酯10%单药、氯菊酯联合伊维菌素、苯甲酸苄酯25%单药均显著优于氯菊酯单药，但不及联合方案。苯甲酸苄酯尤其联合伊维菌素治疗疥疮显著优于单用氯菊酯，在耐药、重度感染或局部治疗依从性差的患者中应优先考虑。 注：如译文有出入，请务必以原文为准。 编者按 本号《皮肤科顶刊速览》栏目，每期将编译JAAD、BJD、JAMA Dermatology、JEADV等皮肤科顶级期刊的最新文献，并精选其中与临床密切相关的文献进行内容简介。旨在使广大皮肤科同道能够便捷、高效了解领域内前沿动态，促进交流、学习、进步。欢迎大家关注、收藏、转发！ 本文版权归作者所有，未经允许，不得转载、摘要、复制、剪辑、录制等。 - 如获得使用许可，必须注明出处，感谢您的支持。 - 欢迎您转发、分享本文，让更多人看到。

DENVER--(BUSINESS WIRE)--Almirall S.A. (ALM), a global biopharmaceutical company dedicated to medical dermatology, is presenting a broad range of clinical and real‑world data across its portfolio at the 2026 American Academy of Dermatology (AAD) Annual Meeting. The company’s presence includes more than 15 scientific posters, led by 9 lebrikizumab presentations in atopic dermatitis (AD), new analyses on tirbanibulin (AK), two on tildrakizumab from the POSITIVE study, and two sarecycline pooled Phase 3 evaluations in acne. "Our goal is to bring meaningful, evidence‑based treatment options to people living with skin diseases. The breadth of data we are sharing at AAD 2026 – from long‑term results and real‑world evidence for lebrikizumab to clinically relevant AK endpoints with tirbanibulin – reflects our commitment to rigorous science, patient‑centred outcomes, and strong collaboration with dermatology partners,” said Dr. Volker Koscielny, Almirall’s Chief Medical Officer. “AAD is an important moment each year to demonstrate our dedication to advancing medical dermatology and patient care. The new data we are sharing underline the real progress made across multiple skin diseases, and our commitment to bringing dermatologists evidence that supports better decision‑making and better care for their patients,” said Paul Rittman, President & General Manager, Almirall U.S. Almirall’s presence at AAD 2026 is an important opportunity to connect with healthcare professionals, partners, and industry peers. AAD 2026 is a leading international forum for medical dermatology expertise and collaboration and takes place March 27–31 in Denver, Colorado. Addressing Unmet Needs in Medical Dermatology Dermatological diseases can exert a profound physical and emotional burden. With a portfolio spanning inflammatory and proliferative skin conditions and an expanding evidence base across both controlled and real‑world settings, Almirall continues to partner with the dermatology community to improve outcomes, experience and long‑term disease control. With over 80 years of experience in healthcare, Almirall is committed to advancing science in dermatology through continuous investment in research and development and by fostering strong partnerships with the medical and scientific communities. The company's expanding portfolio in medical dermatology, particularly its focus on advanced biologic solutions for psoriasis and atopic dermatitis, underscores its dedication to providing innovative dermatological treatments and enhancing patient outcomes. 2026 AAD Annual Meeting poster overview: Almirall and its partners will present more than 15 scientific posters across atopic dermatitis, psoriasis, actinic keratosis and acne, including: Lebrikizumab (Atopic Dermatitis) – 3 Almirall Posters + 6 Eli Lilly Posters Head, neck and face AD in patients with skin of color (ADmirable) 4 year long-term safety and efficacy (ADlong) Real-world effectiveness and advanced systemic pretreated populations (ADLIFE) Improvements in absolute endpoints in real-world settings (ADLIFE) EASI clinical responses across body regions in patients needing >16 weeks to reach EASI 75/IGA 0–1 Clinical feature improvements in skin of color Allergic rhinitis comorbidity and PREPARED‑1 study design Reasons for initiating lebrikizumab in adolescents with moderate-to-severe AD Exposure–response modelling supporting every 8 week maintenance dosing Tildrakizumab (Psoriasis) – 2 Almirall Posters + 4 Sun Pharma Posters Effectiveness of tildrakizumab in patients with moderate-to-severe psoriasis overall and in high-impact areas: 2-year results from the POSITIVE study Beyond skin clearance: Tildrakizumab in moderate-to-severe psoriasis patients – 2-year POSITIVE study results Efficacy and safety of tildrakizumab in patients with moderate-to-severe psoriasis affecting the nails: A multicenter, randomized, double-blind, placebo-controlled, Phase 3b trial Real-World Tildrakizumab Effectiveness in the US by Biologic Experience and Geographic Region in the PPD CorEvitas Psoriasis Registry Real-World Tildrakizumab Persistence in the US by Biologic Experience and Insurance Coverage in the PPD CorEvitas Psoriasis Registry Regional Differences in Patient Characteristics Among US Biologic Initiators from the PPD CorEvitas Psoriasis Registry Tirbanibulin (Actinic Keratosis) – 3 Posters Efficacy beyond complete clearance: percent lesion reduction as a meaningful endpoint Efficacy, safety and tolerability of up to two 5-day treatment courses Achieving complete clearance with mild-to-moderate LSRs: pooled Phase III analysis Sarecycline (Acne) – 2 Posters Truncal acne outcomes: multinational pooled Phase 3 analysis Pooled Phase 3 results in moderate-to-severe facial acne About Klisyri (tirbanibulin) ointment, 1%: INDICATION KLISYRI is a microtubule inhibitor indicated for the topical field treatment of actinic keratosis on the face or scalp. IMPORTANT SAFETY INFORMATION WARNINGS AND PRECAUTIONS Ophthalmic Adverse Reactions Klisyri may cause eye irritation. Avoid transfer of the drug into the eyes and to the periocular area during and after application. Wash hands immediately after application. If accidental exposure occurs, instruct patient to flush eyes with water and seek medical care as soon as possible. Local Skin Reactions Local skin reactions, including severe reactions (erythema, flaking/scaling, crusting, swelling, vesiculation/pustulation, and erosion/ulceration) in the treated area can occur after topical application of Klisyri. Avoid use until skin is healed from any previous drug, procedure, or surgical treatment. Occlusion after topical application of Klisyri is more likely to result in irritation. ADVERSE REACTIONS The most common adverse reactions (incidence ≥2%) were local skin reactions, application site pruritus, and application site pain. Click here to view: Full Prescribing Information About Seysara (sarecycline) tablets: INDICATIONS AND USAGE SEYSARA (sarecycline) tablet 60/100/150 mg, is indicated for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients 9 years of age and older. Limitations of Use: Efficacy of SEYSARA beyond 12 weeks and safety beyond 12 months have not been established. SEYSARA has not been evaluated in the treatment of infections. To reduce the development of drug-resistant bacteria as well as to maintain the effectiveness of other antibacterial drugs, SEYSARA should be used only as indicated. IMPORTANT SAFETY INFORMATION CONTRAINDICATIONS SEYSARA is contraindicated in persons who have shown hypersensitivity to any of the tetracyclines. WARNINGS AND PRECAUTIONS Like other tetracyclines, SEYSARA can cause fetal harm when administered to a pregnant woman. If SEYSARA is used during pregnancy, or if the patient becomes pregnant while taking SEYSARA, the patient should be informed of the potential hazard to the fetus and treatment should be stopped immediately. The use of SEYSARA during tooth development (second and third trimesters of pregnancy, infancy, and childhood up to the age of 8 years) may cause permanent discoloration of the teeth (yellow-gray-brown). Clostridium difficile associated diarrhea (CDAD) has been reported with nearly all antibacterial agents, and may range in severity from mild diarrhea to fatal colitis. If Clostridium difficile Associated Diarrhea (antibiotic associated colitis) occurs, discontinue SEYSARA. Central nervous system side effects , including light-headedness, dizziness or vertigo, have been reported with tetracycline use. Patients who experience these symptoms should be cautioned about driving vehicles or using hazardous machinery. These symptoms may disappear during therapy and may disappear when the drug is discontinued. Intracranial hypertension in adults and adolescents has been associated with the use of tetracyclines. Clinical manifestations include headache, blurred vision and papilledema. Although signs and symptoms of intracranial hypertension resolve after discontinuation of treatment, the possibility for sequelae such as visual loss that may be permanent or severe exists. Concomitant use of isotretinoin and SEYSARA should be avoided because isotretinoin, a systemic retinoid, is also known to cause intracranial hypertension. Photosensitivity manifested by an exaggerated sunburn reaction has been observed in some individuals taking tetracyclines. Patients should minimize or avoid exposure to natural or artificial sunlight (tanning beds or UVA/B treatment) while using SEYSARA. Bacterial resistance to tetracyclines may develop in patients using SEYSARA. Because of the potential for drug-resistant bacteria to develop during the use of SEYSARA, it should only be used as indicated. As with other antibiotic preparations, use of SEYSARA may result in overgrowth of non-susceptible organisms, including fungi. If superinfection occurs, SEYSARA should be discontinued and appropriate therapy instituted. ADVERSE REACTIONS The most common adverse reaction (incidence ≥1%) was nausea: SEYSARA 3.1% vs placebo 2.0%. Please see full Prescribing Information. About Ilumya (tildrakizumab-asmn): INDICATION AND IMPORTANT SAFETY INFORMATION ILUMYA (tildrakizumab-asmn) is indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. CONTRAINDICATIONS ILUMYA is contraindicated in patients with a previous serious hypersensitivity reaction to tildrakizumab or to any of the excipients. WARNINGS AND PRECAUTIONS Hypersensitivity Cases of angioedema and urticaria occurred in ILUMYA-treated subjects in clinical trials. If a serious allergic reaction occurs, discontinue ILUMYA immediately and initiate appropriate therapy. Infections ILUMYA may increase the risk of infection. Treatment with ILUMYA should not be initiated in patients with a clinically important active infection until the infection resolves or is adequately treated. Consider the risks and benefits of treatment prior to prescribing ILUMYA in patients with a chronic infection or a history of recurrent infection. Instruct patients receiving ILUMYA to seek medical help if signs or symptoms of clinically important chronic or acute infection occur. If a patient develops a clinically important or serious infection, or is not responding to standard therapy, closely monitor and consider discontinuation of ILUMYA until the infection resolves. Pretreatment Evaluation for Tuberculosis Evaluate patients for tuberculosis (TB) infection prior to initiating treatment with ILUMYA. Do not administer ILUMYA to patients with active TB infection. Initiate treatment of latent TB prior to administering ILUMYA. Consider anti-TB therapy prior to initiation of ILUMYA in patients with a past history of latent or active TB in whom an adequate course of treatment cannot be confirmed. Patients receiving ILUMYA should be monitored closely for signs and symptoms of active TB during and after treatment. Immunizations Prior to initiating therapy with ILUMYA, consider completion of all age-appropriate immunizations according to current immunization guidelines. Patients treated with ILUMYA should not receive live vaccines. Adverse Reactions The most common (≥1%) adverse reactions associated with ILUMYA treatment that were more frequent than in the placebo group are upper respiratory infections, injection-site reactions, and diarrhea. Please see full Prescribing Information. About Ebglyss (lebrikizumab-lbkz): INDICATION AND SAFETY SUMMARY EBGLYSS is an injectable medicine used to treat adults and children 12 years of age and older who weigh at least 88 pounds (40 kg) with moderate-to-severe eczema (atopic dermatitis) that is not well controlled with prescription therapies used on the skin (topical), or who cannot use topical therapies. EBGLYSS can be used with or without topical corticosteroids. It is not known if EBGLYSS is safe and effective in children less than 12 years of age or in children 12 years to less than 18 years of age who weigh less than 88 pounds (40 kg). Warnings - Do not use EBGLYSS if you are allergic to lebrikizumab-lbkz or to any of the ingredients in EBGLYSS. See the Patient Information leaflet that comes with EBGLYSS for a complete list of ingredients. Before using EBGLYSS, tell your healthcare provider about all your medical conditions, including if you: Have a parasitic (helminth) infection. Are scheduled to receive any vaccinations. You should not receive a "live vaccine" if you are treated with EBGLYSS. Are pregnant or plan to become pregnant. It is not known if EBGLYSS will harm your unborn baby. If you become pregnant during treatment with EBGLYSS, you or your healthcare provider can call Eli Lilly and Company at 1-800-LillyRx (1-800-545-5979) to report the pregnancy. Are breastfeeding or plan to breastfeed. It is not known if EBGLYSS passes into your breast milk. Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Possible side effects EBGLYSS can cause serious side effects, including: Allergic reactions. EBGLYSS can cause allergic reactions that may sometimes be severe. Stop using EBGLYSS and tell your healthcare provider or get emergency help right away if you get any of the following signs or symptoms: Eye problems. Tell your healthcare provider if you have any new or worsening eye problems, including eye pain or changes in vision, such as blurred vision. The most common side effects of EBGLYSS include: eye and eyelid inflammation, including redness, swelling, and itching injection site reactions shingles (herpes zoster) These are not all of the possible side effects of EBGLYSS. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. How to take Use EBGLYSS exactly as prescribed by your healthcare provider. EBGLYSS is given as an injection under the skin (subcutaneous injection). If your healthcare provider decides that you or a caregiver can give the injections of EBGLYSS, you or a caregiver should receive training on the right way to prepare and inject EBGLYSS. Do not try to inject EBGLYSS until you have been shown the right way by your healthcare provider. In children 12 years of age and older, EBGLYSS should be given by a caregiver. If you miss a dose of EBGLYSS, inject the missed dose as soon as possible, then inject your next dose at your regular scheduled time. Learn more EBGLYSS is a prescription medicine available as a 250 mg/2 mL injection prefilled pen or prefilled syringe. For more information, call 1-800-545-5979 or go to ebglyss.lilly.com This summary provides basic information about EBGLYSS but does not include all information known about this medicine. Read the information that comes with your prescription each time your prescription is filled. This information does not take the place of talking to your doctor. Be sure to talk to your doctor or other healthcare provider about EBGLYSS and how to take it. Your doctor is the best person to help you decide if EBGLYSS is right for you. Content addressed for US audience only. About Almirall Almirall is a global biopharmaceutical company dedicated to medical dermatology. We closely collaborate with leading scientists, healthcare professionals, and patients to deliver our purpose: to transform the patients' world by helping them realize their hopes and dreams for a healthy life. We are at the forefront of science to deliver ground-breaking, differentiated medical dermatology innovations that address patients’ needs. Almirall, founded in 1944 and headquartered in Barcelona, is publicly traded on the Spanish Stock Exchange (ticker: ALM, total revenue in 2025: €1114.5 MM, over 2100 employees globally). Almirall products help to improve the lives of patients every day and are available in over 100 countries. For more information, please visit https://www.almirall.com/